Every claim we hold, and how far we can stand behind it.
142 claims across 39 products. 30% are confirmed against the source text by the evidence gate; 39% come from a class with no vendor interest. Everything below is browsable, filterable, and available as JSON.
| Evidence class | Claims | Confirmed | What it can support |
|---|---|---|---|
| Peer-reviewed study | 19 | 5 | Independent review before publication. The only class that survives a sceptical committee unaided. |
| Regulatory filing | 4 | 0 | A statement made to a regulator, where being wrong has consequences. |
| Independent report | 32 | 9 | Analysis by someone with no stake in the sale. |
| Customer case | 4 | 3 | A real deployment, but selected and framed by someone with an interest. |
| Press release | 63 | 23 | The vendor's own announcement. Useful for dates and facts, not for outcomes. |
| Vendor page | 20 | 2 | Marketing copy. Establishes what is claimed, never that it is true. |
Showing 20 of 20 matching claims (142 in the full corpus) · 5% of this selection is confirmed · clear filters
In the physician-validated Harvard-Stanford ARISE NOHARM clinical safety benchmark, Glass ranked among the top medical AI systems, ahead of models from OpenAI and Anthropic; Glass reasons over 38M+ peer-reviewed citations, current clinical guidelines, and 150,000+ FDA drug labels with cited answers
Provenance
- Claim ID
- clm_c3a9fcb6efd65b5dbe47
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://glass.health/features
Wolters Kluwer launched UpToDate Expert AI (GenAI clinical decision support), initially available to Enterprise Edition customers from Q4 2025.
Provenance
- Claim ID
- clm_9a678a93ecd11a7d462a
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- interoperability
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://www.wolterskluwer.com/en/news/uptodate-expert-ai-genai-clinical-decision-support
Approximately 2,500 U.S. hospitals and health systems - over 90% of U.S. UpToDate Enterprise Edition customers - have adopted UpToDate Expert AI, including Sharp HealthCare, Duke University Health System, University of Iowa Health Care, and Intermountain Health (34 sites)
Provenance
- Claim ID
- clm_8e0ef3bd123ceba43277
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- deployment traction
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://markets.ft.com/data/announce/detail?dockey=600-202608060930BIZWIRE_USPRX____20260806_BW987931-1
Peer-reviewed Nature Health study (SAFEMOM) of Ada integrated into South Africa's government-run MomConnect WhatsApp maternal health platform found safe health-seeking behavior rose nearly a third and appropriate care-seeking rose more than 40%; an independent physician panel rated Ada's recommendations safe in 98% of cases
Provenance
- Claim ID
- clm_e424d6e33e196547ba29
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://doi.org/10.1038/s44360-026-00125-x
Infermedica's Medical Guidance Platform (Triage, Intake, Follow-up modules) achieved EU MDR Class IIb certification, one of the highest compliance levels for Software as a Medical Device in Europe; Conversational Triage, its agentic neurosymbolic AI product launched April 2025, is in the process of MDR certification expected 2026
Provenance
- Claim ID
- clm_62f80b6c194758cc9caf
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- trust governance
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://infermedica.com/blog/articles/infermedica-2025-a-year-in-review
Infermedica's solutions crossed 25 million completed health checkups and, with Healthdirect Australia, generated a 71% increase in self-assessment completion rates, a 9% improvement in triage accuracy, and a 46% reduction in overtriage versus the legacy system, serving 26 million Australians
Provenance
- Claim ID
- clm_9c06762efec404b82938
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- deployment traction
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://infermedica.com/blog/articles/infermedica-2025-a-year-in-review
Since launching in September 2025, Wolters Kluwer has been working with more than 50 major U.S. health systems to deploy UpToDate Expert AI enterprise-wide, and added comprehensive medication information from UpToDate Lexidrug (~3,000 drug topics) to the AI
Provenance
- Claim ID
- clm_5ec75a7962d25f6855a0
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- deployment traction
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://www.wolterskluwer.com/en/news/uptodate-expert-ai-genai-clinical-decision-support
OpenEvidence, a tool that doctors and nurses have likened to ChatGPT for medicine, planned to announce a $200 million raise at a $6 billion valuation; the round was led by Google Ventures, with participation from Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft, and its number of clinical consultations per month has nearly doubled to 15 million since July.
Provenance
- Claim ID
- clm_13448bdf904435ba7eda
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- economic value
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://techcrunch.com/2025/10/20/openevidence-the-chatgpt-for-doctors-raises-200m-at-6b-valuation/
Wolters Kluwer launched UpToDate Expert AI, a generative AI CDS solution grounded solely in UpToDate evidence-based content with transparent assumptions and rationale, available to select UpToDate Enterprise Edition customers beginning Q4 2025
Provenance
- Claim ID
- clm_320b2741e1f8af156542
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- general
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://www.wolterskluwer.com/en/news/uptodate-expert-ai-genai-clinical-decision-support
The July 2025 announcement introduced the wide release of DeepConsult, with the feature free to verified U.S. clinicians, expanding Glass AI's clinical reasoning capabilities
Provenance
- Claim ID
- clm_9d055fa3533df063eee3
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- deployment traction
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://glass.health/compare/openevidence
Mayo Clinic study in J Prim Care Community Health (2025 Apr 16;16:21501319251332215, doi 10.1177/21501319251332215) found OpenEvidence 'provided accurate, evidence-based recommendations in all cases, aligning with physician plans' across five common chronic conditions, with mean scores of clarity 3.55±0.60, relevance 3.75±0.44, support 3.35±0.49, and satisfaction 3.60±0.60.
Provenance
- Claim ID
- clm_565ce01a474e2b680115
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12033599/
Glass AI launched a Developer API for its clinical decision support platform, enabling third parties to build custom integrations (including ambient scribing workflows)
Provenance
- Claim ID
- clm_908a501ff7ccd0b4b6f7
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- interoperability
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://www.linkedin.com/posts/glass-health-inc_glass-health-developer-api-ambient-scribing-activity-7382480136790515712-_nDE
Infermedica was named to AVIA Marketplace's 2024 Top Clinical Decision Support Companies list
Provenance
- Claim ID
- clm_3c80a940dcc5c13cfb92
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- market durability
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://www.prnewswire.com/news-releases/infermedica-named-to-avia-marketplaces-2024-top-clinical-decision-support-companies-302280884.html
Glass Health (YC W23) launched an LLM-powered tool that generates differential diagnoses and evidence-based treatment options from clinician-entered patient summaries, with roughly $6.5M in total funding including a $5M seed led by Initialized Capital
Provenance
- Claim ID
- clm_b2412c30d73fb2826021
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- general
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://techcrunch.com/2023/09/08/glass-health-is-building-an-ai-for-suggesting-medical-diagnoses/
Ada's medical AI solutions are available on the Epic App Orchard marketplace using SMART on FHIR open standards, with single sign-on (SSO) supporting integration into MyChart patient portals
Provenance
- Claim ID
- clm_0b65d1c12b422b4a5960
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- interoperability
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://about.ada.com/press/220315-ada-healths-medical-ai-solutions-now-available-on-epic-app-orchard
Ada closed its Series B at $120M: $90M led by Leaps by Bayer (May 2021) plus a $30M extension from Farallon Capital, Red River West and Bertelsmann Investments (Feb 2022), with Schroders Capital acquiring secondary shares; total funding ~$189M
Provenance
- Claim ID
- clm_fb263852bb4e2fd81471
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- market durability
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://about.ada.com/press/220210-ada-health-extends-series-b-to-120-million
Infermedica raised a $30M Series B led by One Peak (January 2022), bringing total funding to roughly $44M, to expand its AI-based medical guidance platform
Provenance
- Claim ID
- clm_aadc47ac08fc4c144849
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- market durability
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://techcrunch.com/2022/01/25/infermedica-raises-30m-to-expand-its-ai-based-medical-guidance-platform/
Journal of Investigative Dermatology study (Dulmage et al., 2021;141:1230-1235, doi 10.1016/j.jid.2020.08.027) of VisualDx's point-of-care AI system found 'The AI system achieved an accuracy of 68% in determining the single most likely morphology from the test image bank', while primary care physicians scored 36% without aids and 68% with a visual guide (P < 0.001); on 222 images across Fitzpatrick skin types the AI achieved 70% accuracy in Fitzpatrick I-III and 68% in Fitzpatrick IV-VI (P = 0.79).
Provenance
- Claim ID
- clm_19dcf624d235238fa2b7
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://doi.org/10.1016/j.jid.2020.08.027
Independent BMJ Open peer-reviewed vignette study (Gilbert et al., 2020) compared digital symptom assessment apps, including Ada, against GPs for suggesting conditions and urgency advice
Provenance
- Claim ID
- clm_796e5c36fb879e0a483b
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7745718/
Cluster-randomized controlled trial in J Med Libr Assoc (2019 Apr 1;107(2):151-162, doi 10.5195/jmla.2019.581) evaluated VisualDx as a clinical evidence technology for skin problems in primary care: 'Thirty-two PCPs and 433 patients participated', and time from index visit to skin problem resolution was similar in both groups (hazard ratio=0.92; 95% CI 0.70, 1.21; p=0.54).
Provenance
- Claim ID
- clm_fa1a96f540b206b3d969
- Version
- 1
- Workflow
- Clinical Evidence & Decision Support
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6466492/